(183490) –
-
Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting
-
Enzychem Lifesciences Announces Acceptance of EC-18 Abstract for Oral Proffered Paper at the MASCC/ISOO 2022 Annual Meeting
-
Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting
-
Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis
-
Enzychem Lifesciences Announces Formation of Corporate Advisory Committee
-
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea
-
Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis
-
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis
-
Enzychem Lifesciences Announces Database Lock for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis
-
Enzychem Lifesciences to Present at BIO Digital 2021
-
Enzychem Lifesciences Announces Poster Presentation at the 2021 Keystone Symposia Conference
-
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program
-
Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The International Liver Congress 2021 (EASL)
-
Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis
-
Enzychem Lifesciences Selected to Participate at the 15th New York Health Forum: Investing in Space - Next Frontier of Healthcare
-
Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)
-
Enzychem Lifesciences Announces Poster Presentation At AACR Virtual Annual Meeting 2021
-
Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space
-
Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021
-
Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia
-
Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia
-
Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug
-
Enzychem Lifesciences Initiates Phase 2 Study for EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to Novel Coronavirus Pneumonia
-
Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology
-
Enzychem Lifesciences Announces Filing of U.S. Provisional Patent for EC-18 for the Treatment of COVID-19
-
Enzychem Lifesciences Announces Plans to Advance Clinical Trial in South Korea for EC-18 as a Potential Therapeutic for COVID-19 Infection
-
Enzychem Lifesciences Appoints Dr. Michael Charlton To Its Scientific Advisory Board
-
Enzychem Lifesciences To Present At Biotech Showcase™ 2020 In San Francisco
-
Enzychem Lifesciences announces collaborative Material Transfer Agreement (MTA) with the Armed Forces Radiobiology Research Institute (AFRRI) for the Development of a Radiation Medical Countermeasure.
-
Enzychem Lifesciences Presents EC-18 NASH Development Update at The Liver Meeting 2019
-
Enzychem Lifesciences Announces Poster Presentation at Liver Meeting 2019
-
Enzychem Lifesciences Announces Three Abstracts Accepted at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Enzychem Lifesciences Announces Poster Presentations at the AACR 2019 Annual Meeting
-
Enzychem Lifesciences Completes Stage 1 Patient Enrollment in Phase 2 CRIOM Study
-
Enzychem Lifesciences To Present At Biotech Showcase™ 2019 In San Francisco
-
Enzychem Lifesciences held Launch Ceremony in USA
-
Enzychem Lifesciences held Launch Ceremony in USA
-
Enzychem Lifesciences' Growth Continues in US, Adds Jeff Clark as New Chief Licensing Officer
-
Enzychem Lifesciences' Fast Track Designation for chemo-radiation induced oral mucositis had been granted by the FDA
-
Enzychem Lifesciences announces the FDA Orphan Drug Designation granted to EC-18 on Acute Radiation Syndrome (ARS)
-
Enzychem Lifesciences Announces Initiation of Global Phase 2 Trial of EC-18 in Patients with Chemotherapy Induced Neutropenia(CIN)
Back to 183490 Stock Lookup
